Xander Bradeen

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Chemotherapy Induced

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Bradley M Haverkos, Jasmine M Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Ajay Major, Steven Bair, Jagar Jasem, Clayton Smith, Diana Abbott, Pierluigi Porcu
Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial. Blood advances 8 (3) (2024)
Bradley M Haverkos, Jasmine M Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Ajay Major, Steven Bair, Jagar Jasem, Clayton Smith, Diana Abbott, Pierluigi Porcu
Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial. Blood advances 8 (3) (2024)
Bradley M Haverkos, Jasmine M Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Ajay Major, Steven Bair, Jagar Jasem, Clayton Smith, Diana Abbott, Pierluigi Porcu
Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial. Blood advances 8 (3) (2024)
Bradley M Haverkos, Jasmine M Zain, Manali Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Ajay Major, Steven M Bair, Jagar Jasem, Clayton Smith, Diana Abbott, Pierluigi Porcu
Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted EPOCH in Peripheral T-cell Lymphoma: A Phase I Trial. Blood advances (2023)